Both intradermal injection of IL-23 and the topical application of IMQ induce psoriasis-like keratinocyte proliferation, thickening of epidermis and dermal inflammation7, 15, 16, 17, 18, which is mediated by IL-22 and IL-17A7, 11, 16, 18. Here, IL23A is linked to psoriasis.